Scholarlink

Background <p>Anemia affects pediatric quality of life. It can cause hypoxia and loss of concentration. There are a lot of iron supplements used in treating pediatric CKD-induced anemia our study aimed to evaluate the effectiveness of oral liposomal iron in treating pediatric CKD anemia compared tointravenous iron dextran.</p> Methods <p>This randomized, parallel study was conducted on 60 CKD pediatric patients. The patients were categorized into two groups. Group 1 comprises 30 pediatric patients administered oral liposomal iron 30 mg/day for 3 months. Group 2 comprises 30 pediatric patients administered intravenous iron dextran 50 mg three times/ week for 3 months.</p> Results <p>Both groups have no statistically significant difference in Hb, RBCS, MCV, PLTs, RDW-CV, Cr, Hepcidin, Ferritin, Iron, and Transferrin levels after 3 months of treatment. Liposomal iron has higher efficacy than IV dextran after 3 months of treatment since there is a significant difference within the group between before and after treatment period at Hb, RBCS, HCT, MCV, RDW-CV, Hepcidin, Ferritin, Iron, TIBC, and Transferrin levels with no reported side effects during the study period.</p> Conclusion <p>Oral liposomal iron has higher efficacy than IV dextran, which is the traditional CKD anemia treatment in pediatric with no reported side effects.</p> Impact <p><UnorderedList Mark="Bullet"> <ItemContent> <p>The key message of our article is to determine a safe, effective, easy to use, and less costly treatment of chronic kidney disease anemia in pediatrics.</p> </ItemContent> <ItemContent> <p>Our study will add to the existing literature a suggestion of an effective and safe treatment for pediatric chronic disorder, the traditional treatment has a lot of serious side effects.</p> </ItemContent> <ItemContent> <p>The impact of our study is to treat anemia resulted from chronic kidney disease in pediatrics with oral drug that has higher efficacy than the traditional injectable drug, this will lead to higher rate of anemia treatment due to higher rate of children compliance.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Liposomal iron dramatic effect on chronic kidney disease pediatric anemia: a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Sahar Kamal Hegazy,
  • Mai Salah El-Din Koura,
  • Mohamed Shokry Elharoun

摘要

Background

Anemia affects pediatric quality of life. It can cause hypoxia and loss of concentration. There are a lot of iron supplements used in treating pediatric CKD-induced anemia our study aimed to evaluate the effectiveness of oral liposomal iron in treating pediatric CKD anemia compared tointravenous iron dextran.

Methods

This randomized, parallel study was conducted on 60 CKD pediatric patients. The patients were categorized into two groups. Group 1 comprises 30 pediatric patients administered oral liposomal iron 30 mg/day for 3 months. Group 2 comprises 30 pediatric patients administered intravenous iron dextran 50 mg three times/ week for 3 months.

Results

Both groups have no statistically significant difference in Hb, RBCS, MCV, PLTs, RDW-CV, Cr, Hepcidin, Ferritin, Iron, and Transferrin levels after 3 months of treatment. Liposomal iron has higher efficacy than IV dextran after 3 months of treatment since there is a significant difference within the group between before and after treatment period at Hb, RBCS, HCT, MCV, RDW-CV, Hepcidin, Ferritin, Iron, TIBC, and Transferrin levels with no reported side effects during the study period.

Conclusion

Oral liposomal iron has higher efficacy than IV dextran, which is the traditional CKD anemia treatment in pediatric with no reported side effects.

Impact

The key message of our article is to determine a safe, effective, easy to use, and less costly treatment of chronic kidney disease anemia in pediatrics.

Our study will add to the existing literature a suggestion of an effective and safe treatment for pediatric chronic disorder, the traditional treatment has a lot of serious side effects.

The impact of our study is to treat anemia resulted from chronic kidney disease in pediatrics with oral drug that has higher efficacy than the traditional injectable drug, this will lead to higher rate of anemia treatment due to higher rate of children compliance.